Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.

PubWeight™: 1.77‹?› | Rank: Top 3%

🔗 View Article (PMID 12176871)

Published in Blood on September 01, 2002

Authors

Ian R Wanless1, George Sweeney, Amar P Dhillon, Maria Guido, Antonio Piga, Renzo Galanello, M Rita Gamberini, Elias Schwartz, Alan R Cohen

Author Affiliations

1: Department of Laboratory Medicine and Pathobiology, Toronto General Hospital and University of Toronto, ON, Canada. ian.wanless@utoronto.ca

Articles citing this

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag (2007) 1.14

Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. PLoS One (2012) 1.13

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol (2012) 1.00

Friedreich ataxia-update on pathogenesis and possible therapies. Neurogenetics (2003) 0.93

Thalassaemia major: the murky story of deferiprone. BMJ (2004) 0.91

Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90

Deferiprone and hepatic fibrosis. Blood (2003) 0.85

Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol (2012) 0.82

Reductions in post-hepatectomy liver failure and related mortality after implementation of the LiMAx algorithm in preoperative work-up: a single-centre analysis of 1170 hepatectomies of one or more segments. HPB (Oxford) (2015) 0.79

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med (2015) 0.78

Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study. Evid Based Complement Alternat Med (2007) 0.78

Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut (2007) 0.77

Quantitative assessment of iron in heart and liver phantoms using dual-energy computed tomography. Exp Ther Med (2014) 0.76

Development and Validation of a Terbium-Sensitized LuminescenceAnalytical Method for Deferiprone. Iran J Pharm Res (2012) 0.75

Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol (2016) 0.75

Articles by these authors

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07

Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17

Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A (2005) 4.64

Retraction of an interpretation. Lancet (2004) 3.55

Complications of beta-thalassemia major in North America. Blood (2004) 2.97

A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92

Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75

Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64

Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol (2006) 2.61

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54

Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53

Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52

Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41

On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33

Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood (2004) 2.27

Beta-thalassemia. Genet Med (2010) 2.24

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14

Purging iron from the heart. Br J Haematol (2004) 2.07

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood (2012) 2.04

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98

Reduced ventricular shunt rate in very preterm infants with severe intraventricular hemorrhage: an institutional experience. J Neurosurg Pediatr (2012) 1.98

A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87

Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81

A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2009) 1.78

Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76

End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73

KLF1 gene mutations cause borderline HbA(2). Blood (2011) 1.71

In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70

Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68

Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65

Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range. J Biomed Opt (2012) 1.62

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl (2009) 1.60

Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59

Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58

The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology (2010) 1.56

Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol (2007) 1.56

Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl (2009) 1.55

An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer (2010) 1.55

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology (2008) 1.52

The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int (2010) 1.51

Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am (2002) 1.50

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49

Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol (2009) 1.48

Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46

An agenda for children for the 113th Congress: recommendations from the pediatric academic societies. Pediatrics (2012) 1.45

Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion (2013) 1.43

Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades. Dig Liver Dis (2010) 1.42

Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42

Endoscopic transventricular selective amygdalohippocampectomy: cadaveric demonstration of a new operative approach. World Neurosurg (2012) 1.40

The "swing-ding": a golf-related head injury in children. J Neurosurg Pediatr (2011) 1.40

Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40

The birth and evolution of neuroscience through cadaveric dissection. Neurosurgery (2010) 1.39

Neurological injuries from car surfing. J Neurosurg Pediatr (2009) 1.39

Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol (2007) 1.34

A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol (2006) 1.34

A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood (2002) 1.31

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology (2006) 1.27

Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26

Scoring of chronic hepatitis. Clin Liver Dis (2002) 1.25

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis (2007) 1.24

Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24

Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica (2008) 1.24

Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver (2002) 1.24

Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica (2011) 1.23

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood (2011) 1.23

Pathophysiology of beta thalassaemia. Pediatr Endocrinol Rev (2011) 1.22

Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol (2004) 1.22

Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord (2011) 1.21

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21

Franc D. Ingraham and the genesis of pediatric neurosurgery. J Neurosurg Pediatr (2013) 1.18